American Journal of Obstetrics & Gynecology
Volume 181, Issue 5, Supplement , Pages S45-S52 , November 1999

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol

References 

  1. Mishell DR. Oral contraception: past, present, and future perspectives. Int J Fertil. 1992;37(suppl 1):7–18
  2. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol. 1992;21:48–52
  3. Archer DF, Maheux R, DelConte A, O’Brien FB. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 μg and ethinyl estradiol 20 μg. Contraception. 1997;55:139–144
  4. Bannemerschult R, Hanker JP, Wunsch C, Fox P, Albring M, Brill K. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel over six treatment cycles. Contraception. 1997;56:285–290
  5. Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 1986;34:253–260
  6. DelConte A, Loffer F, Grubb G. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: a multicenter, randomized, comparative trial of levonorgestrel/ethinyl estradiol 100 μg/20 μg and norethindrone acetate/ethinyl estradiol 1000 μg/20 μg. Contraception. 1999;54:187–193
  7. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinyl estradiol 100 μg/20 μg versus triphasic norethindrone/ethinyl estradiol 500-750-1000 μg/35 μg: a multicenter, randomized open-label study. Eur J Contracept Reprod Health Care. 1999;4:75–83
  8. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept. 1992;8(suppl 1):35–45
  9. Van der Vange N. Ovarian activity during low dose oral contraceptives. In:  Chamberlain G editors. Contemporary obstetrics and gynecology. London: Butterworths; 1988;p. 315–326
  10. Wilde MI, Balfour JA. Gestodene: a review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs. 1995;50:364–395
  11. Fotherby K. Pharmacokinetics and metabolism of progestins in humans. In:  Goldzieher JW editors. Pharmacology of the contraceptive steroids. New York: Raven Press; 1994;p. 99–126
  12. Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M, Orme ML, et al.  The pharmacokinetics of levonorgestrel and ethinyl estradiol in women: studies with Ovral and Ovranette. Contraception. 1981;23:229–239
  13. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH, et al.  Kinetics of norethindrone in women, II: single-dose kinetics. Clin Pharmacol Ther. 1978;24:448–453
  14. Schilling LH, Bolding OT, Chenault CB, Chong AP, Fleury F, Forrest K, et al.  Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial. Am J Obstet Gynecol. 1989;160:1264–1268
  15. Droegemueller W, Katta LR, Bright TG, Bowes WA. Triphasic randomized clinical trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989;161:1407–1411
  16. Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol. 1996;88(3 suppl):4S–12S
  17. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. BMJ. 1980;280:1157–1161
  18. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–88
  19. Meirik O. Cardiovascular safety and combined oral contraceptives. Contraception. 1998;57:135–136
  20. Thorogood M. Stroke and steroid hormonal contraception. Contraception. 1998;57:157–167
  21. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1998;57:169–181
  22. World Health Organization Scientific Group . Steroid contraception and the risk of neoplasia. Geneva: The Organization; 1978; Technical report series No.: 619

☆ Supported by Wyeth-Ayerst Research, Philadelphia, Pa.

☆☆ Reprint requests: Howard Reisman, MD, Atlanta North Gynecology, PC, 11050 Crabapple Rd, Suite 111D, Roswell, GA 30075.

★ 0002-9378/99 $8.00 + 0 6/0/102577

PII: S0002-9378(99)70363-7

American Journal of Obstetrics & Gynecology
Volume 181, Issue 5, Supplement , Pages S45-S52 , November 1999

Article Tools